Scholar Rock Holding Corporation SRRK R2KR3KPHARMA
Company Overview
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +73.01% |
| 6 Months: | +22.17% |
| 3 Months: | +24.90% |
| 1 Month: | +5.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corporation R2KR3KPHARMA | 55.33 | -16.72 | $6.74B | 0.00% | -110.26% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | 0 | 3.11M | 5.04M | 4.77M | 5.03M | 3.90M | 3.04M | 4.71M | 4.59M | 5.46M | 33.19M | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
| Operating Income | -5.89M | -5.94M | -9.02M | -14.88M | -11.23M | -11.70M | -13.39M | -17.11M | -17.69M | -19.46M | -23.62M | -27.21M | -30.27M | -37.08M | -6.93M | -43.15M | -43.86M | -40.51M | -39.08M | -43.67M | -58.42M | -59.50M | -64.78M | -77.09M | -112.11M | -103.55M | -102.02M | -108.90M |
| Net Income | -5.88M | -5.93M | -8.89M | -14.71M | -10.76M | -10.76M | -12.53M | -16.15M | -17.07M | -19.28M | -23.56M | -27.67M | -30.71M | -37.51M | -7.95M | -44.00M | -43.30M | -39.38M | -37.92M | -42.36M | -56.85M | -58.51M | -64.48M | -74.72M | -110.03M | -102.22M | -105.51M | -109.90M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.79 | -0.76 | -0.84 | -1.02 | -0.21 | -1.06 | -0.55 | -0.49 | -0.47 | -0.53 | -0.59 | -0.60 | -0.66 | -0.67 | -0.98 | -0.90 | -0.83 | -0.84 |
| R&D Expense | 4.71M | 4.78M | 6.70M | 11.42M | 8.06M | 10.74M | 13.71M | 15.70M | 16.90M | 17.00M | 18.38M | 22.55M | 25.60M | 31.27M | 29.37M | 32.07M | 33.39M | 29.73M | 26.87M | 30.34M | 43.09M | 42.37M | 48.72M | 48.68M | 62.40M | 50.49M | 51.81M | 58.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 20.49M | 15.40M | 18.82M | 33.19M | - | - | 0 |
| Operating Income | -25.03M | -50.69M | -54.54M | -86.88M | -129.92M | -134.37M | -171.29M | -252.05M | -384.64M |
| Net Income | -25.00M | -49.33M | -51.00M | -86.48M | -131.80M | -134.50M | -165.79M | -246.29M | -377.94M |
| Diluted EPS | - | - | - | -2.81 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 |
| R&D Expense | 19.94M | 36.31M | 54.22M | 74.06M | 108.47M | 124.44M | 121.90M | 184.55M | 208.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 61.64M | 181.34M | 196.38M | 388.31M | 304.44M | 358.17M | 311.04M | 474.92M | 404.27M |
| Total Equity | -30.03M | -53.52M | 106.62M | 112.90M | 260.77M | 172.07M | 260.24M | 225.22M | 368.63M | 245.49M |
| Cash & Equivalents | - | 56.46M | 115.07M | 36.31M | 160.36M | 212.84M | 103.28M | 101.86M | 177.88M | 323.53M |
| Long Term Debt | - | - | - | - | 24.68M | 48.42M | 49.74M | 48.68M | 50.15M | 99.71M |
| Total Liabilities | - | 5.93M | 74.71M | 83.48M | 127.53M | 132.37M | 97.93M | 85.82M | 106.29M | 158.78M |
| Current Liabilities | - | 5.02M | 31.12M | 32.81M | 42.56M | 64.30M | 36.39M | 32.74M | 46.94M | 55.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.74M | 24.57M | -63.12M | -60.27M | -126.79M | -132.69M | -145.23M | -200.95M | -300.04M |
| Investing Cash Flow | 17.66M | -60.23M | -62.24M | -63.50M | 134.31M | -171.70M | 41.14M | -76.06M | 218.69M |
| Financing Cash Flow | 50.50M | 94.27M | 48.88M | 247.82M | 44.95M | 194.83M | 102.57M | 353.03M | 228.40M |
| Capital Expenditure | -361.00K | -1.49M | -3.12M | -4.09M | -5.25M | -1.06M | -71.00K | -98.00K | -602.00K |
| Free Cash Flow | -22.10M | 23.08M | -66.23M | -64.36M | -132.04M | -133.76M | -145.30M | -201.05M | -300.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -266.2% | -564.0% | -690.5% | -404.8% | - | - | - |
| Net Margin % | - | - | -248.9% | -561.5% | -700.5% | -405.2% | - | - | - |
| ROE % | 46.7% | -46.3% | -45.2% | -33.2% | -76.6% | -51.7% | -73.6% | -66.8% | -154.0% |
| ROCE % | -44.2% | -33.7% | -33.3% | -25.1% | -54.1% | -41.8% | -61.6% | -58.9% | -110.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.78% | 18.00M | $1.04B |
| 2 | Siren, L.L.C. | 7.86% | 9.58M | $553.44M |
| 3 | Blackrock Inc. | 7.80% | 9.49M | $548.76M |
| 4 | Samsara BioCapital, LLC | 5.66% | 6.90M | $398.68M |
| 5 | Price (T.Rowe) Associates Inc | 5.58% | 6.79M | $392.74M |
| 6 | Wellington Management Group, LLP | 5.52% | 6.73M | $388.83M |
| 7 | Orbis Allan Gray Ltd | 4.87% | 5.93M | $342.96M |
| 8 | Vanguard Capital Management LLC | 3.91% | 4.77M | $275.58M |
| 9 | State Street Corporation | 3.88% | 4.73M | $273.32M |
| 10 | Redmile Group, LLC | 3.54% | 4.31M | $249.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SRRK
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise (NASDAQ:SRRK) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQbm1YMWpINzBDYzlFdWlSZ0N2QS1OQUJmZnZoN1JmdVdGTGNUcTVlMVo4YzlVQnJnTktIUWFpMmFkM3dXNzhQOEdTWG4zRVE4NE1jVzJCaGlEaGJob1hwUGhWV0p5S0JxWDJzNU1yUldnazg0TGg1MVpHQ2M2MWNkTkJmYmNyc3FPNC1xUn…
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQNDM5ZllLdUN6YVc3cm93MVltSGc2V1dVbWNTSjZDcldKeGVnNVZ4V29GNFFwcll2MDRjcl9Oc19WMXVCN2xYcEx2M1RBbnBHLW1UZDhXRUszRG4xVTVYdGFBV2R4NmpmYVFPWUppYl93TFozNXA0RFdhZTczMWM5NmxnOG5NRUROUXhoWU…
Scholar Rock Holding (SRRK) Stock Dropped, So What Is Behind The Latest Attention? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNVU91RHdVc1QtRTREazNubEZwRXpLRG1peUlQMmtkbUYtX0VkLTBGSm5YbjBPVnF4QWRTMFdabGk5Wm1YNGxhd1BtaVJHbGJtVFluMnRKa0MxT2tUSFNNR1VkdzJTYVdaY3I2Nzc2OFNnNVBZb25PYnVhcGc1Vnk2X0FGVFNCeF9wWlRWZX…
Scholar Rock is prepared to launch its SMA drug if FDA approves by Sept. 30 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQU1JwbHZNSDl0Q3RPZzRxNktpY3JGMk5VWXl4a012b2dCemVFb2Y2UDhNLURhenJKNVFqS1RJMjk0ejhYUWZkOFRHeGhpY09VRGJfSk5JNXV5bWlUelJ2bFExSTJZR2lqQ1JPOTIzMGI4dmxDNVFxMkxvd2l4dXI2ZEN5ajk0NGpMT1pOQm…
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdnJGMk9lcF9CTXVJRUNBdk1BendvU29Gbm5pME80N3hnaG9zcnNiR011YXNxYmhLa3RCalJXSkY0aDRCMktJNGoteFV1M01iMUR4T2pXZVVYWDhacHA1cVFGTllCOGVoWVQ1UmhkUVlmWmtoVjROZTRCLVJ2S1FLdmYtZTU5UWlPbzI5U2…
Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNQl9Ea1lPLUtIa3BTWGNlbHBEN3ZpcWV0eEZDSkhlSHJ0aHpHTlRjTFNGUjZUdXNKd2Foc25rRXNPQ28yYmJwQUJoenU0SDlpaWRna29ESkRvWk5vNnM5a0haZWEyWTgwek1kMG5JRXJCUThFWXBkUmdidWJxZWs0TzdfaDhPb3pnR3RpOU…
SRRK — Frequently Asked Questions
What is the current share price of Scholar Rock Holding Corporation (SRRK)?
As of 2026-09-07 16:24 PDT, Scholar Rock Holding Corporation (SRRK) trades at $55.33 on NasdaqGS. Its 52-week range is $27.92 to $60.04.
What is the market capitalisation of SRRK?
Scholar Rock Holding Corporation (SRRK) has a market capitalisation of $6.74B on NasdaqGS.
What is the P/E ratio of SRRK?
SRRK trades at a trailing price-to-earnings (P/E) ratio of -16.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 22.84.
Is SRRK a good stock to buy?
This page provides a data-driven analysis of Scholar Rock Holding Corporation (SRRK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.